Integrin antagonists
US6017925A · kind A · utility
34Cited by
7References
25Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 13, 1998 |
| Grant date | Jan 25, 2000 |
| Priority date | — |
| Expiry date | Jan 13, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.